Leerink Partnrs Has Pessimistic View of AXSM FY2027 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Analysts at Leerink Partnrs cut their FY2027 earnings estimates for shares of Axsome Therapeutics in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $5.90 per share for the year, down from their prior forecast of $6.45. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($5.04) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2028 earnings at $10.40 EPS.

AXSM has been the subject of a number of other research reports. Wells Fargo & Company began coverage on shares of Axsome Therapeutics in a research report on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 target price for the company. Bank of America upgraded shares of Axsome Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $95.00 to $106.00 in a research report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and issued a $180.00 target price on shares of Axsome Therapeutics in a report on Thursday, September 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 price target on shares of Axsome Therapeutics in a report on Monday, September 16th. Finally, Robert W. Baird boosted their price objective on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $124.93.

Axsome Therapeutics Trading Down 4.3 %

Shares of AXSM stock opened at $93.17 on Thursday. Axsome Therapeutics has a 1-year low of $56.66 and a 1-year high of $105.00. The company has a current ratio of 2.44, a quick ratio of 2.40 and a debt-to-equity ratio of 1.97. The stock has a market cap of $4.52 billion, a price-to-earnings ratio of -14.27 and a beta of 1.26. The stock has a 50-day moving average of $90.66 and a 200-day moving average of $84.27.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period in the prior year, the business posted ($1.32) earnings per share.

Institutional Trading of Axsome Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Axsome Therapeutics in the second quarter valued at about $27,000. EntryPoint Capital LLC purchased a new stake in Axsome Therapeutics in the 1st quarter valued at about $35,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $47,000. Russell Investments Group Ltd. boosted its stake in shares of Axsome Therapeutics by 5,550.0% in the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock worth $63,000 after buying an additional 777 shares during the last quarter. Finally, Covestor Ltd grew its holdings in shares of Axsome Therapeutics by 54,750.0% in the first quarter. Covestor Ltd now owns 1,097 shares of the company’s stock valued at $88,000 after acquiring an additional 1,095 shares in the last quarter. 81.49% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Mark E. Saad sold 11,016 shares of the company’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total value of $1,005,870.96. Following the sale, the director now owns 10,002 shares in the company, valued at $913,282.62. This represents a 52.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 22.40% of the stock is owned by company insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.